SCHEMBL2790280

SCHEMBL2790280

Cc1cc(C(F)(F)F)nc2c(C(F)(F)F)cccc12

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 1/20 0.48
L3MBTL1 Q9Y468 1/20 0.48
KCNH2 Q12809 8/20 0.47
ADORA2A P29274 5/20 0.47
ADORA1 P30542 5/20 0.47
CYP3A4 P08684 4/20 0.47
ADORA3 P0DMS8 2/20 0.47
CYP2D6 P10635 2/20 0.47
KDM4E B2RXH2 2/20 0.47
ADORA2B P29275 1/20 0.47
CYP2C19 P33261 1/20 0.47
ABCG2 Q9UNQ0 1/20 0.47
NR1I2 O75469 1/20 0.47
LMNA P02545 1/20 0.47
TP53 P04637 1/20 0.47
CYP1A2 P05177 1/20 0.47
HTR1A P08908 1/20 0.47
TSHR P16473 1/20 0.47
CNR1 P21554 1/20 0.47
GLRA1 P23415 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6479303 0.84 KDM4E (0.59) ALDH1A1L3MBTL1KCNH2CYP3A4KDM4E
SCHEMBL1258312 0.83 KCNH2 (0.47) ALDH1A1L3MBTL1KCNH2ADORA2AADORA1
SCHEMBL1655812 0.81 KCNH2 (0.49) ALDH1A1L3MBTL1KCNH2ADORA2AADORA1
SCHEMBL30604783 0.81 KCNH2 (0.46) ALDH1A1L3MBTL1KCNH2ADORA2AADORA1
SCHEMBL30604781 0.81 KCNH2 (0.46) ALDH1A1L3MBTL1KCNH2ADORA2AADORA1
SCHEMBL7689636 0.81 KCNH2 (0.46) ALDH1A1L3MBTL1KCNH2ADORA2AADORA1
SCHEMBL2790491 0.81 KCNH2 (0.46) ALDH1A1L3MBTL1KCNH2ADORA2AADORA1
SCHEMBL31690946 0.81 BACE1 (0.50) ALDH1A1L3MBTL1CYP3A4KDM4ELMNA
SCHEMBL2608426 0.81 CYP2D6 (0.46) ALDH1A1L3MBTL1KCNH2ADORA2AADORA1
SCHEMBL1147111 0.81 KCNH2 (0.46) ALDH1A1L3MBTL1KCNH2ADORA2AADORA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9926326-B2 Substituted thioxanthenone autophagy inhibitors THE CLEVELAND CLINIC FOUNDATION (US) 2018-03-27 US disclosed
US-20170210746-A1 SUBSTITUTED THIOXANTHENONE AUTOPHAGY INHIBITORS THE CLEVELAND CLINIC FOUNDATION 2017-07-27 US disclosed
US-9610317-B2 4-amino-4-oxobutanoyl peptides as inhibitors of viral replication ACHILLION PHARMACEUTICALS, INC. (US) 2017-04-04 US disclosed
US-20160082069-A1 4-AMINO-4-OXOBUTANOYL PEPTIDES AS INHIBITORS OF VIRAL REPLICATION ACHILLION PHARMACEUTICALS, INC. 2016-03-24 US disclosed
US-9233136-B2 4-amino-4-oxobutanoyl peptides as inhibitors of viral replication ACHILLION PHARMACEUTICALS, INC. (US) 2016-01-12 US disclosed
US-9133115-B2 4-amino-4-oxobutanoyl peptides as inhibitors of viral replication ACHILLION PHARMACEUTICALS, INC. (US) 2015-09-15 US disclosed
US-20140328796-A1 4-AMINO-4-OXOBUTANOYL PEPTIDES AS INHIBITORS OF VIRAL REPLICATION ACHILLION PHARMACEUTICALS, INC. 2014-11-06 US disclosed
US-8785378-B2 Macrocyclic peptides as inhibitors of viral replication ACHILLION PHARMACEUTICALS, INC. (US) 2014-07-22 US disclosed
US-20140113890-A1 NEW 4-AMINO-4-OXOBUTANOYL PEPTIDES AS INHIBITORS OF VIRAL REPLICATION ACHILLION PHARMACEUTICALS, INC. (US) 2014-04-24 US disclosed
US-8445430-B2 Cyclic carboxamide compounds and analogues thereof as of hepatitis C virus ACHILLION PHARMACEUTICALS, INC. (US) 2013-05-21 US disclosed
US-20130116169-A1 INHIBITORS OF SERINE PROTEASES, PARTICULARLY HCV NS3-NS4A PROTEASE VERTEX PHARMACEUTICALS INCORPORATED (US) 2013-05-09 US disclosed
WO-2010144102-A1 PENTAFLUOROSULFANYL ANALOGS OF MEFLOQUINE THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY OF THE ARMY, ON BEHALF OF U.S. ARMY MEDICAL RESEARCH AND MATERIAL COMMAND (US) 2010-12-16 WO disclosed
WO-2010144434-A1 DERIVATIVES OF MEFLOQUINE AND ASSOCIATED METHODS FOR MAKING AND USING THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY OF THE ARMY, ON BEHALF OF U.S. (US) 2010-12-16 WO disclosed
WO-2004009121-A1 PHARMACEUTICAL COMPOSITIONS COMPRISING HEPATITIS C VIRAL PROTEASE INHIBITORS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) 2004-01-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130116169-A1 INHIBITORS OF SERINE PROTEASES, PARTICULARLY HCV NS3-NS4A PROTEASE SERPINB1, PRSS1, SPINT2 ALDH1A1 2015/4885L3MBTL1 1764/4885KCNH2 4716/4885
US-20160082069-A1 4-AMINO-4-OXOBUTANOYL PEPTIDES AS INHIBITORS OF VIRAL REPLICATION ZC3HAV1, VIP, ZC3HAV1L ALDH1A1 3885/4885L3MBTL1 2124/4885KCNH2 3213/4885
US-20140113890-A1 NEW 4-AMINO-4-OXOBUTANOYL PEPTIDES AS INHIBITORS OF VIRAL REPLICATION ZC3HAV1, VIP, ZC3HAV1L ALDH1A1 4204/4885L3MBTL1 785/4885KCNH2 2000/4885
US-20140328796-A1 4-AMINO-4-OXOBUTANOYL PEPTIDES AS INHIBITORS OF VIRAL REPLICATION VIP, ZC3HAV1, CCL5 ALDH1A1 4010/4885L3MBTL1 847/4885KCNH2 2243/4885
US-20170210746-A1 SUBSTITUTED THIOXANTHENONE AUTOPHAGY INHIBITORS BECN1, ATG7, SQSTM1 ALDH1A1 3286/4885L3MBTL1 606/4885KCNH2 3221/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.